Richard shares his thoughts on our new Neuropathy product, our growth plans in the US and those key differences between the US and other markets. He also discusses the impact of chemotherapy-induced hair loss and why it remains such an important part of our mission to improve the cancer treatment experience.
The podcast also features analyst Maria Karlsson Osipova, who explores the fundamentals of Paxman and explains key areas including scalp cooling, reimbursement, IBBM and CIPN – and what investors need to understand in order to follow Paxmans growth journey forward.

Richard’s interview starts at 18 minutes, we hope you enjoy listening!